Seven tumor markers in benign and malignant germ cell tumors of the ovary

Kawai, Michiyasu; Kano, T; Kikkawa, Fumitaka; Morikawa, Yoshimitsu; Oguchi, Hidenori; Nakashima, Naoki; Ishizuka, Takao; Kuzuya, Kazuo; Ohta, Makoto; Arii, Yoshitaro; Tsutsumi, Yutaka

doi:10.1016/0090-8258(92)90299-x

Cited by 90 publications

(54 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In MCT, the mean levels of SCC and CA125 tended to be high, although they were within the normal range. CA19-9 is known to be a good marker for MCT, 5 and the mean level was above the cutoff value (37 U/mL) in the current study. On the other hand, the mean CEA level was quite low in patients with MCT, and none of them were positive.…”

Section: Resultsmentioning

confidence: 93%

Diagnosis of squamous cell carcinoma arising from mature cystic teratoma of the ovary

Kikkawa

Nawa

Koji

et al. 1998

Cancer

Self Cite

169

159

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 93%

Diagnosis of squamous cell carcinoma arising from mature cystic teratoma of the ovary

Kikkawa

Nawa

Koji

et al. 1998

Cancer

Self Cite

169

159

View full text Add to dashboard Cite

show abstract

“…Tumor marker production by the tumor (AFP by endodermal sinus tumor, HCG by choriocarcinoma, HCG and/or LDH by some dysgerminomas, and CA-125 sometimes by all tumors) has been demonstrated by changes in serum levels following surgical removal of the tumor and/or following chemotherapy [17][18][19][20][21]. In the present series, elevated levels of serum tumor markers either before or immediately following surgery were noted in seven of the 11 patients in whom serum tumor markers were evaluated (some patients had more than one elevated serum tumor marker).…”

Section: Discussionmentioning

confidence: 99%

Malignant germ cell tumors of the ovary: A study of 20 cases

Piura

Dgani

Zalel

et al. 1995

Journal of Surgical Oncology

View full text Add to dashboard Cite

In a study of 20 patients diagnosed with malignant ovarian germ cell tumors between 1961 and 1993, clinical and pathologic findings were evaluated. Of the 20 patients, seven (35%) had dysgerminoma, two (10%) endodermal sinus tumor, three (15%) malignant teratoma, one (5%) malignant struma ovarii, one (5%) primary ovarian carcinoid, two (10%) benign teratoma with malignant transformation, and four (20%) combination germ cell tumor. Twelve patients (60%) had stage IA, five (25%) stage IC, and three (15%) stage IIIC. Twelve patients (60%) underwent conservative surgery and eight (40%) had at least bilateral salpingo-oophorectomy. At follow-up, 18 patients (90%) were alive free of disease, one (5%) had died of disease, and one (5%) had died of intercurrent disease. The actuarial 5-year survival rate was 93.3%. It is concluded that for young women who wish to preserve child-bearing capacity, regardless of the stage of the tumor, fertility-preserving surgery with complete surgical staging followed, if necessary by cisplatin-based combination chemotherapy is an appropriate and definitive treatment in the absence of involvement of the contralateral ovary and uterus. For patients in whom child-bearing capacity is not an issue, surgery should include total abdominal hysterectomy and bilateral salpingo-oophorectomy with complete staging, followed if necessary by chemotherapy.

show abstract

“…5 They concluded that among age, tumor size, serum CEA levels, and serum SCC levels, the combined two criteria of patient's age (under 40 years old or younger) and serum SCC level (under 2.5 ng/ml) is a suitable marker for differential diagnosis between benign mature cystic teratomas and malignant transformation. Kawai et al 6 studied seven tumor markers in ovarian tumors and reported that CA 19-9 showed a high positive rate in teratomatous tumors which were immature teratoma, mature cystic teratoma with malignant transformation, and mature cystic teratoma. Kikkawa et al 7 reported that age and tumor size are important factors in making a differential diagnosis, and recommended that serum SCC and CEA levels should be measured in patients older than 45 years who have a mature cystic teratoma-like ovarian tumor larger than 99 mm in the greatest diameter.…”

Section: Discussionmentioning

confidence: 99%

Adenocarcinoma arising in mature cystic teratoma: a case report

et al. 2008

View full text Add to dashboard Cite

Benign cystic teratoma is recognized as one of the most common tumors in women during the reproductive age and frequently is treated by pelviscopic operation. Malignant transformation of a benign cystic teratoma is a rare event, and adenocarcinoma is extremely rare, and distinguishing this malignant change from benign disease preoperatively is nearly impossible even by the use of radiological imaging or various tumor markers. Therefore, patients should be informed that if a laparoscopic cystectomy is undertaken, a prompt second staging operation should be performed if the definitive pathology reveals an unexpected malignancy. We present a case with thyroid papillary carcinoma of follicular variant arising from mature cystic teratoma removed by laparoscopic salpingo-oophorectomy followed by staging laparotomy. We briefly reviewed literatures with regard to malignant transformation of a benign cystic teratoma.

show abstract

Seven tumor markers in benign and malignant germ cell tumors of the ovary

Cited by 90 publications

References 9 publications

Diagnosis of squamous cell carcinoma arising from mature cystic teratoma of the ovary

Diagnosis of squamous cell carcinoma arising from mature cystic teratoma of the ovary

Malignant germ cell tumors of the ovary: A study of 20 cases

Adenocarcinoma arising in mature cystic teratoma: a case report

Contact Info

Product

Resources

About